Edwards Lifesciences (EW) Cash from Financing Activities (2009 - 2026)

Edwards Lifesciences has reported Cash from Financing Activities for 18 years, with the latest figure at -$451.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 74.88% year-over-year to -$451.2 million; the trailing twelve-month figure through Mar 2026 stood at -$1.2 billion (up 11.72% YoY), and the FY2025 full-year result was -$956.8 million, up 2.67% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$451.2 million, down from -$11.4 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $61.7 million in Q1 2024, with the low at -$976.7 million in Q3 2024.
• Average Cash from Financing Activities over 5 years is -$275.7 million, with a median of -$206.6 million recorded in 2023.
• Year-over-year, Cash from Financing Activities plunged 1252.26% in 2022 and surged 154.55% in 2025.
• Tracing EW's Cash from Financing Activities over 5 years: stood at -$838.4 million in 2022, then jumped by 50.72% to -$413.2 million in 2023, then soared by 106.92% to $28.6 million in 2024, then sank by 139.86% to -$11.4 million in 2025, then tumbled by 3857.89% to -$451.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$451.2 million (Q1 2026), -$11.4 million (Q4 2025), and -$740.1 million (Q3 2025), per Business Quant data.

Peer Comparison